Astrana Health, Inc. (ASTH) vs Immunome, Inc. (IMNM)

A side-by-side comparison of Astrana Health, Inc. and Immunome, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Astrana Health, Inc. logo
ASTH
Astrana Health, Inc.
$1.84B
$37.12HealthcareDelayed quote: Oct 6, 2026, 10:45 AM EDT
Immunome, Inc. logo
IMNM
Immunome, Inc.
$1.93B
$20.23HealthcareDelayed quote: Oct 6, 2026, 10:40 AM EDT

Total return — ASTH vs IMNM

growth of $100 · dividends reinvested · last 6y
ASTH +105.2% (+12.7%/yr)IMNM +57.4% (+7.9%/yr)ASTH compounded faster over this window
0200400600Start $100202120222023202420252026$205$157
ASTH IMNM

ASTH vs IMNM: by the numbers

  • •IMNM is the larger company ($1.93B vs $1.84B market cap).
  • •ASTH is profitable (1.05% net margin) while IMNM runs a net loss (-3059.99%).

Metrics side by side

Valuation

MetricASTHIMNM
P/E ratio45.40N/A
Forward P/E26.55N/A
P/S ratio0.48N/A
P/B ratio2.223.68
EV / EBITDA13.52N/A
FCF yield8.61%N/A

Profitability

MetricASTHIMNM
Gross margin9.22%57.43%
Operating margin2.61%-3084.76%
Net margin1.05%-3059.99%
ROE4.88%-48.43%
ROIC4.13%-51.06%

Growth (annualized)

MetricASTHIMNM
Revenue CAGR (5Y)53.77%N/A
EPS CAGR (5Y)-15.06%N/A
FCF CAGR (5Y)18.35%N/A
Total return CAGR (5Y)-16.52%2.88%

Frequently asked

Is ASTH or IMNM more profitable?
ASTH runs the higher net margin — ASTH at 1.05% versus IMNM at -3059.99%.
How have ASTH and IMNM total returns compared?
Over the past 5 years, ASTH delivered -16.52% and IMNM delivered 2.88% annualized total return. Past performance doesn't predict future results.

Go deeper

Full ASTH analysisFull IMNM analysisInteractive comparison tool

Dig into the metrics

Astrana Health P/E ratioAstrana Health ROEImmunome ROEAstrana Health operating marginImmunome operating marginAstrana Health revenue growthImmunome revenue growthAstrana Health free cash flowImmunome free cash flow

Astrana Health & Immunome appear in these rankings

Fastest Revenue Growth StocksHighest FCF Yield StocksHighest 10-Year Total Return Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.